These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 33840176)

  • 1. Role of Krebs von den Lungen-6 (KL-6) in Assessing Hypersensitivity Pneumonitis.
    Mostafa AI; Salem AE; Ahmed HAM; Bayoumi AI; Halim RMA; Samie RMA
    Tuberc Respir Dis (Seoul); 2021 Jul; 84(3):200-208. PubMed ID: 33840176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of KL-6/MUC1 in the clinical management of interstitial lung diseases.
    Ishikawa N; Hattori N; Yokoyama A; Kohno N
    Respir Investig; 2012 Mar; 50(1):3-13. PubMed ID: 22554854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. YKL-40 and KL-6 Levels in Serum and Sputum of Patients Diagnosed With Hypersensitivity Pneumonitis.
    Sánchez-Díez S; Munoz X; Ojanguren I; Romero-Mesones C; Espejo D; Villar A; Gómez-Olles S; Cruz MJ
    J Allergy Clin Immunol Pract; 2022 Sep; 10(9):2414-2423. PubMed ID: 35788062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Krebs von den Lungen-6 as biomarker of the new progressive fibrotic phenotype of interstitial lung disease.
    d'Alessandro M; Conticini E; Bergantini L; Mazzei MA; Bellisai F; Selvi E; Cameli P; Frediani B; Bargagli E
    Tissue Cell; 2024 Oct; 90():102516. PubMed ID: 39137538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Krebs von den Lungen-6 associated with chest high-resolution CT score in evaluation severity of patients with interstitial lung disease.
    Qin H; Xu XP; Zou J; Zhao XJ; Wu HW; Zha QF; Chen S; Kang Y; Jiang HD
    Pulmonology; 2019; 25(3):143-148. PubMed ID: 30007895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Krebs von den lungen-6 as a clinical marker for hypersensitivity pneumonitis: A meta-analysis and bioinformatics analysis.
    He J; Zhang J; Ren X
    Front Immunol; 2022; 13():1041098. PubMed ID: 36532009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Krebs von den Lungen-6 as a biomarker for disease severity assessment in interstitial lung disease: a comprehensive review.
    d'Alessandro M; Bergantini L; Cameli P; Vietri L; Lanzarone N; Alonzi V; Pieroni M; M Refini R; Sestini P; Bonella F; Bargagli E
    Biomark Med; 2020 Jun; 14(8):665-674. PubMed ID: 32613855
    [No Abstract]   [Full Text] [Related]  

  • 9. Role of serum surfactant protein-D as a prognostic predictor in fibrotic hypersensitivity pneumonitis.
    Ejima M; Okamoto T; Suzuki T; Miyazaki Y
    Respir Investig; 2022 May; 60(3):369-378. PubMed ID: 34998715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Krebs von den Lungen-6 (KL-6) is a pathophysiological biomarker of early-stage acute hypersensitivity pneumonitis among pigeon fanciers.
    Ji Y; Bourke SJ; Spears M; Wain LV; Boyd G; Lynch PP; Cunningham M; Boyd K; Donnelly I; Kohno N; McSharry C
    Clin Exp Allergy; 2020 Dec; 50(12):1391-1399. PubMed ID: 32966647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
    Ma H; Lu J; Song Y; Wang H; Yin S
    BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of serum Krebs von den Lungen-6 levels with fibrosis score on high resolution chest tomography and pulmonary function parameters in treatment naïve Idiopathic Pulmonary Fibrosis.
    Sanjan G; Sharma P; Banerjee S; Sivaramakrishnan P; Sherwani P; Atif Mirza A; Sindhwani G; Arvind Bahurupi Y
    Sarcoidosis Vasc Diffuse Lung Dis; 2024 Sep; 41(3):e2024044. PubMed ID: 39315978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
    Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
    Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The usefulness of KL-6 and SP-D for the diagnosis and management of chronic hypersensitivity pneumonitis.
    Okamoto T; Fujii M; Furusawa H; Tsuchiya K; Miyazaki Y; Inase N
    Respir Med; 2015 Dec; 109(12):1576-81. PubMed ID: 26481343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in serum KL-6 levels during short-term strict antigen avoidance are associated with the prognosis of patients with fibrotic hypersensitivity pneumonitis caused by avian antigens.
    Hanzawa S; Tateishi T; Ishizuka M; Inoue Y; Honda T; Kawahara T; Tomita M; Miyazaki Y
    Respir Investig; 2020 Nov; 58(6):457-464. PubMed ID: 32698996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Biomarkers in a Radiological Pattern of Non-Fibrotic Hypersensitivity Pneumonitis: Implications for Mechanistic Difference and Differential Diagnosis.
    Takimoto T; Nakamura Y
    Diseases; 2022 Jun; 10(3):. PubMed ID: 35892730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Krebs von den Lungen-6 and lung ultrasound B lines as potential diagnostic and prognostic factors for rheumatoid arthritis-associated interstitial lung disease.
    Fotoh DS; Helal A; Rizk MS; Esaily HA
    Clin Rheumatol; 2021 Jul; 40(7):2689-2697. PubMed ID: 33474659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.
    Chiu YH; Chu CC; Lu CC; Liu FC; Tang SE; Chu SJ; Kuo SY; Chen HC
    J Inflamm Res; 2022; 15():2255-2262. PubMed ID: 35422651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analytical and Clinical Performance of the Nanopia Krebs von den Lungen 6 Assay in Korean Patients With Interstitial Lung Diseases.
    Cho EJ; Park KJ; Ko DH; Koo HJ; Lee SM; Song JW; Lee W; Lee HK; Do KH; Chun S; Min WK
    Ann Lab Med; 2019 May; 39(3):245-251. PubMed ID: 30623616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic Performance of CLEIA Versus FEIA for KL-6 Peripheral and Alveolar Concentrations in Fibrotic Interstitial Lung Diseases: A Multicentre Study.
    d'Alessandro M; Gangi S; Paggi I; Soccio P; Bergantini L; Pianigiani T; Montuori G; Moriondo G; Natalello G; Marrucci S; Brogna A; Scioscia G; Lacedonia D; Cameli P; Bargagli E
    J Clin Lab Anal; 2024 Oct; 38(19-20):e25108. PubMed ID: 39323282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.